Scharf Investments Has Lowered By $63.05 Million Its Advance Auto Parts (AAP) Holding; Enanta Pharmaceuticals (ENTA) Has 1.29 Sentiment

Enanta Pharmaceuticals Inc (ENTA) investors sentiment decreased to 1.29 in Q2 2018. It’s down -0.21, from 1.5 in 2018Q1. The ratio worsened, as 93 investment managers increased and opened new stock positions, while 62 decreased and sold positions in Enanta Pharmaceuticals Inc. The investment managers in our database now have: 14.64 million shares, up from 14.18 million shares in 2018Q1. Also, the number of investment managers holding Enanta Pharmaceuticals Inc in top ten stock positions was flat from 2 to 2 for the same number . Sold All: 16 Reduced: 46 Increased: 59 New Position: 34.

Scharf Investments Llc decreased Advance Auto Parts Inc (AAP) stake by 33.14% reported in 2018Q2 SEC filing. Scharf Investments Llc sold 467,046 shares as Advance Auto Parts Inc (AAP)’s stock rose 25.94%. The Scharf Investments Llc holds 942,095 shares with $127.85 million value, down from 1.41 million last quarter. Advance Auto Parts Inc now has $12.22 billion valuation. The stock decreased 4.65% or $8.17 during the last trading session, reaching $167.59. About 761,799 shares traded. Advance Auto Parts, Inc. (NYSE:AAP) has risen 71.81% since December 8, 2017 and is uptrending. It has outperformed by 56.19% the S&P500. Some Historical AAP News: 02/04/2018 – Advance Auto Parts Reaffirms Full-Year Guidance; 23/05/2018 – Advance Auto Parts Grapples With Higher Fuel Costs; 22/05/2018 – ADVANCE AUTO PARTS SAYS EFFECTIVE MAY 16, BOARD ABOLISHED STANDING FINANCE COMMITTEE – SEC FILING; 02/04/2018 – ADVANCE AUTO PARTS INC – TOM OKRAY HAS DECIDED TO LEAVE ORGANIZATION, EFFECTIVE APRIL 15, 2018; 02/04/2018 – W W GRAINGER – MOST RECENTLY, OKRAY SERVED AS EVP AND CFO FOR ADVANCE AUTO PARTS; 02/04/2018 – Advance Auto Parts Announces CFO Transition; 29/03/2018 AAP IMPLANTATE – MADE SUBSTANTIAL PROGRESS IN PREPARING HUMAN CLINICAL STUDY FOR AIMED CE AND FDA APPROVAL OF ITS ANTIBACTERIAL SILVER COATING TECHNOLOGY IN RECENT MONTHS; 22/05/2018 – Advance Auto Parts 1Q Net $136.7M; 02/04/2018 – Advance Auto Parts CFO Okray to Leave to Join Another Company; 29/03/2018 – AAP IMPLANTATE AG AAQG.DE – AIMS TO START HUMAN CLINICAL STUDY IN COURSE OF CURRENT FINANCIAL YEAR

Since August 17, 2018, it had 1 buy, and 1 insider sale for $13,559 activity. TRAVIS NIGEL also bought $199,625 worth of Advance Auto Parts, Inc. (NYSE:AAP) on Friday, August 17. $186,066 worth of stock was sold by DIAS FIONA P on Friday, November 16.

More notable recent Advance Auto Parts, Inc. (NYSE:AAP) news were published by: Seekingalpha.com which released: “Advance Auto Parts raised FY2018 guidance – Seeking Alpha” on November 13, 2018, also Investorplace.com with their article: “The Massive Growth in AAP Stock Could Stall Out – Investorplace.com” published on November 08, 2018, Globenewswire.com published: “Market Trends Toward New Normal in Five Below, The Hanover Insurance Group, Advance Auto Parts, Kosmos Energy, LyondellBasell Industries NV, and Vornado Realty Trust — Emerging Consolidated Expectations, Analyst Ratings – GlobeNewswire” on November 29, 2018. More interesting news about Advance Auto Parts, Inc. (NYSE:AAP) were released by: Investorplace.com and their article: “AutoZone Earnings Prime a Selling Opportunity in AZO Stock – Investorplace.com” published on December 04, 2018 as well as Fool.com‘s news article titled: “Why General Electric, Advance Auto Parts, and Vodafone Jumped Today – The Motley Fool” with publication date: November 13, 2018.

Investors sentiment increased to 1.2 in Q2 2018. Its up 0.16, from 1.04 in 2018Q1. It is positive, as 35 investors sold AAP shares while 131 reduced holdings. 63 funds opened positions while 109 raised stakes. 72.49 million shares or 4.78% less from 76.12 million shares in 2018Q1 were reported. Adage Capital Partners Group Inc Ltd Company reported 1.28 million shares or 0.4% of all its holdings. Texas-based Dimensional Fund Advisors Limited Partnership has invested 0.03% in Advance Auto Parts, Inc. (NYSE:AAP). Diversified Tru Commerce holds 0.02% or 1,959 shares. Champlain Inv Ptnrs Ltd Limited Liability Company owns 779,930 shares for 1.02% of their portfolio. Tocqueville Asset Management LP has 0.01% invested in Advance Auto Parts, Inc. (NYSE:AAP) for 7,681 shares. Bluecrest Capital Mgmt owns 6,092 shares. 8,049 were reported by Comml Bank Of Nova Scotia. Gulf Int Savings Bank (Uk) Limited has 0.04% invested in Advance Auto Parts, Inc. (NYSE:AAP). Shine Advisory Svcs Inc has 350 shares for 0.02% of their portfolio. Envestnet Asset reported 0.01% in Advance Auto Parts, Inc. (NYSE:AAP). Pub Employees Retirement Association Of Colorado stated it has 13,094 shares. Trexquant Lp owns 0.2% invested in Advance Auto Parts, Inc. (NYSE:AAP) for 21,722 shares. Asset Mgmt holds 10,582 shares. Raymond James Advsrs holds 2,213 shares. Shellback Ltd Partnership holds 1.51% or 152,500 shares.

Analysts await Advance Auto Parts, Inc. (NYSE:AAP) to report earnings on February, 20. They expect $1.15 earnings per share, up 49.35% or $0.38 from last year’s $0.77 per share. AAP’s profit will be $83.83M for 36.43 P/E if the $1.15 EPS becomes a reality. After $1.89 actual earnings per share reported by Advance Auto Parts, Inc. for the previous quarter, Wall Street now forecasts -39.15% negative EPS growth.

Among 10 analysts covering Advance Auto Parts (NYSE:AAP), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Advance Auto Parts had 18 analyst reports since June 12, 2018 according to SRatingsIntel. The company was maintained on Wednesday, November 14 by UBS. The rating was upgraded by Citigroup on Wednesday, August 15 to “Neutral”. The stock of Advance Auto Parts, Inc. (NYSE:AAP) earned “Underperform” rating by Bank of America on Wednesday, June 27. The rating was maintained by Deutsche Bank on Wednesday, August 15 with “Buy”. Morgan Stanley maintained Advance Auto Parts, Inc. (NYSE:AAP) rating on Wednesday, August 15. Morgan Stanley has “Overweight” rating and $170 target. The stock of Advance Auto Parts, Inc. (NYSE:AAP) has “Overweight” rating given on Friday, June 15 by JP Morgan. The company was maintained on Friday, June 22 by UBS. As per Friday, October 26, the company rating was maintained by Wedbush. The firm has “Overweight” rating given on Wednesday, November 14 by JP Morgan. The rating was maintained by Credit Suisse on Wednesday, November 14 with “Outperform”.

The stock decreased 1.91% or $1.42 during the last trading session, reaching $73.03. About 351,022 shares traded or 27.78% up from the average. Enanta Pharmaceuticals, Inc. (ENTA) has risen 110.33% since December 8, 2017 and is uptrending. It has outperformed by 94.71% the S&P500. Some Historical ENTA News: 08/05/2018 – ENANTA PHARMACEUTICALS INC – ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MLN DUE TO INCREASE IN ABBVIE’S MAVYRET SALES; 12/04/2018 – Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH at The International Liver Congress™ 2018; 08/05/2018 – Enanta Pharmaceuticals 2Q EPS 61c; 08/05/2018 – ENANTA 2Q EPS 61C, EST. 53C; 19/03/2018 Enanta at Investor Day Hosted By H.C. Wainwright Today; 14/05/2018 – Janus Henderson Group Buys New 2.6% Position in Enanta; 08/05/2018 – Enanta Pharmaceuticals 2Q Rev $44M; 24/04/2018 – Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second; 21/05/2018 – Enanta at JMP Securities Life Sciences Conference Jun 20; 09/05/2018 – ENANTA PHARMACEUTICALS INC ENTA.O : RBC RAISES TARGET PRICE TO $100.00 FROM $80

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Nasdaq.com which released: “After-Hours Earnings Report for November 26, 2018 : ENTA, BKE, MTSC, GSM – Nasdaq” on November 26, 2018, also Nasdaq.com with their article: “Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy? – Nasdaq” published on November 19, 2018, Seekingalpha.com published: “Enanta Pharma FQ4 top line down 12%; earnings down 25%; shares down 1% after hours – Seeking Alpha” on November 26, 2018. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Benzinga.com and their article: “Earnings Scheduled For November 26, 2018 – Benzinga” published on November 26, 2018 as well as Businesswire.com‘s news article titled: “Enanta Announces that AbbVie’s MAVYRETâ„¢ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis – Business Wire” with publication date: November 13, 2018.

Since January 1, 0001, it had 0 insider purchases, and 5 insider sales for $6.27 million activity.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.42 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 18.47 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on February, 6. They expect $1.64 EPS, up 110.26% or $0.86 from last year’s $0.78 per share. ENTA’s profit will be $31.87 million for 11.13 P/E if the $1.64 EPS becomes a reality. After $1.30 actual EPS reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 26.15% EPS growth.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.